Subscribe
shutterstock_607718810_vchal
vchal / Shutterstock.com
4 June 2019Genetics

Danish biotech company secures CRISPR licence

Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Charpentier granted new CRISPR/Cas9 patent
23 April 2019   ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Americas
Charpentier granted new CRISPR/Cas9 patent
23 April 2019   ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.

More on this story

Americas
Charpentier granted new CRISPR/Cas9 patent
23 April 2019   ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.
Biotechnology
ERS Genomics signs CRISPR deal with Lonza
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent